BM-613, a new thromboxane A2 antagonist, is characterized by a preferential activity on platelet thromboxane A2 receptors

Hanson, Julien; Rolin, S.; De Leval, X.; Neven, P.; De Leval, Laurence; Masereel, B.; Pirotte, Bernard; Dogné, Jean-Michel

Paper published in a journal (Scientific congresses and symposiums)

Hanson, Julien; Rolin, S.; De Leval, X. et al.

2003 • In Blood, p. 813a-814

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/21967

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

abstract Blood 2003 2.pdf

Publisher postprint (164.78 kB)

Request a copy

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Disciplines :

Pharmacy, pharmacology & toxicology

Author, co-author :

Hanson, Julien ; Université de Liège - ULiège > Département de pharmacie > Chimie pharmaceutique

Rolin, S.; Centre Hospitalier Universitaire de Liège - CHU > Anatomie pathologique

De Leval, X.; Université de Liège - ULiège > Département de pharmacie > Chimie pharmaceutique

Neven, P.; Université de Liège - ULiège > Département de pharmacie > Département de pharmacie

De Leval, Laurence

Masereel, B.

Pirotte, Bernard

Dogné, Jean-Michel

Language :

English

Title :

BM-613, a new thromboxane A2 antagonist, is characterized by a preferential activity on platelet thromboxane A2 receptors

Publication date :

2003

Audience :

International

Journal title :

Blood

ISSN :

0006-4971

eISSN :

1528-0020

Publisher :

American Society of Hematology, Washington, United States - District of Columbia

Special issue title :

102

Pages :

813a-814a

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 11 September 2009

Statistics

Number of views

85 (17 by ULiège)

Number of downloads

0 (0 by ULiège)

More statistics